Regulatory Roundup: FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA released this week a final guidance on anticounterfeiting excipients. The guidance recommends that any physical–chemical identifier incorporated into solid oral dosage forms of drugs be pharmacologically inactive. Quality, potency, and bioavailability are also discussed.

FDA, the Centers for Medicare (CMS), and Medicaid launched a pilot program last week to conduct parallel reviews of medical devices, which are seeking FDA approval as well as Medicare coverage. “The FDA and CMS anticipate that parallel review will facilitate the development of innovative new products and increase the efficiency of the review processes for both agencies,” according to an agency press release. The two-year pilot is voluntary and will not change the existing separate and distinct review standards for FDA device approval and CMS coverage determination.

FDA also announced a joint study with NIH on tobacco use and risk. The large-scale, national study will monitor tobacco users to assess the behavioral and health impacts of new government tobacco regulations, namely the 2009 Family Smoking Prevention and Tobacco Control.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here